• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.一项关于认知行为疗法辅助强迫症药物治疗的随机对照试验。
Am J Psychiatry. 2008 May;165(5):621-30. doi: 10.1176/appi.ajp.2007.07091440. Epub 2008 Mar 3.
2
Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.认知行为疗法与利培酮辅助治疗强迫症中选择性 5-羟色胺再摄取抑制剂:一项随机临床试验。
JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932.
3
Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.认知行为疗法作为5-羟色胺再摄取抑制剂治疗强迫症的辅助疗法:一项开放性试验。
J Clin Psychiatry. 1999 Sep;60(9):584-90. doi: 10.4088/jcp.v60n0904.
4
Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.随机对照试验的 6 个月随访结果,该试验在治疗强迫症时增强了 5-羟色胺再摄取抑制剂的治疗作用,并采用了暴露和仪式预防。
J Clin Psychiatry. 2013 May;74(5):464-9. doi: 10.4088/JCP.12m08017.
5
Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.认知行为疗法联合药物治疗儿童强迫症:儿科强迫症治疗研究 II(POTS II)随机对照试验。
JAMA. 2011 Sep 21;306(11):1224-32. doi: 10.1001/jama.2011.1344.
6
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.暴露与仪式预防、氯米帕明及其联合治疗强迫症的随机安慰剂对照试验。
Am J Psychiatry. 2005 Jan;162(1):151-61. doi: 10.1176/appi.ajp.162.1.151.
7
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.对强迫症药物治疗无反应者增加认知行为疗法:一项自然主义研究。
J Clin Psychiatry. 2007 Oct;68(10):1552-6. doi: 10.4088/jcp.v68n1013.
8
Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.暴露/反应预防强化治疗后停药的强迫症患者的健康维持:一项随机临床试验
JAMA Psychiatry. 2022 Mar 1;79(3):193-200. doi: 10.1001/jamapsychiatry.2021.3997.
9
Issues in the pharmacological treatment of obsessive-compulsive disorder.强迫症药物治疗中的问题
Int J Clin Pract. 2007 Jul;61(7):1188-97. doi: 10.1111/j.1742-1241.2007.01356.x. Epub 2007 May 18.
10
Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.行为疗法与选择性 5-羟色胺再摄取抑制剂药物治疗强迫症的对照随机临床试验的系统评价和荟萃分析。
Depress Anxiety. 2014 Aug;31(8):641-52. doi: 10.1002/da.22232. Epub 2014 Jan 3.

引用本文的文献

1
Convergent molecular signatures across eating disorders and obsessive-compulsive disorder in the human brain.人类大脑中饮食失调和强迫症的趋同分子特征。
medRxiv. 2024 Nov 28:2024.11.27.24318078. doi: 10.1101/2024.11.27.24318078.
2
Exposure and response prevention versus stress management training for adults and adolescents with obsessive compulsive disorder: A randomized clinical trial.暴露与反应预防疗法与应激管理训练治疗成人与青少年强迫症的随机临床试验
Behav Res Ther. 2024 Jan;172:104458. doi: 10.1016/j.brat.2023.104458. Epub 2023 Dec 12.
3
Changes in Brain Network Connections After Exposure and Response Prevention Therapy for Obsessive-Compulsive Disorder in Adolescents and Adults.青少年和成人强迫症暴露和反应预防治疗后大脑网络连接的变化。
Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Jan;9(1):70-79. doi: 10.1016/j.bpsc.2023.09.009. Epub 2023 Oct 10.
4
Identifying trajectories of symptom change in adults with obsessive compulsive disorder receiving exposure and response prevention therapy.识别接受暴露和反应预防治疗的强迫症成年人症状变化轨迹。
J Anxiety Disord. 2023 May;96:102711. doi: 10.1016/j.janxdis.2023.102711. Epub 2023 Apr 7.
5
The therapeutic alliance in cognitive-behavioral therapy for obsessive-compulsive disorder: A systematic review and meta-analysis.强迫症认知行为疗法中的治疗联盟:一项系统评价与荟萃分析
Front Psychiatry. 2022 Sep 6;13:951925. doi: 10.3389/fpsyt.2022.951925. eCollection 2022.
6
The efficacy of brief strategic therapy in treating obsessive-compulsive disorder: a case series.简短策略治疗治疗强迫症的疗效:病例系列。
Acta Biomed. 2022 Sep 22;93(S1):e2022271. doi: 10.23750/abm.v93iS1.13064.
7
Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.暴露/反应预防强化治疗后停药的强迫症患者的健康维持:一项随机临床试验
JAMA Psychiatry. 2022 Mar 1;79(3):193-200. doi: 10.1001/jamapsychiatry.2021.3997.
8
Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.最大限度地实现接受药物治疗的强迫症成年患者从认知行为疗法中缓解。
Behav Res Ther. 2021 Aug;143:103890. doi: 10.1016/j.brat.2021.103890. Epub 2021 May 29.
9
HOW IMPORTANT IS THE THERAPEUTIC ALLIANCE IN TREATING OBSESSIVE-COMPULSIVE DISORDER WITH EXPOSURE AND RESPONSE PREVENTION? AN EMPIRICAL REPORT.治疗联盟在采用暴露与反应阻止法治疗强迫症中有多重要?一份实证报告。
Clin Neuropsychiatry. 2016 Dec;13(6):88-93.
10
Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.成人强迫症药物治疗的专业知识和能力标准。
Psychiatry Res. 2021 Jun;300:113853. doi: 10.1016/j.psychres.2021.113853. Epub 2021 Mar 4.

本文引用的文献

1
Practice guideline for the treatment of patients with obsessive-compulsive disorder.强迫症患者治疗实践指南。
Am J Psychiatry. 2007 Jul;164(7 Suppl):5-53.
2
Treatment of obsessive-compulsive disorder by U.S. psychiatrists.美国精神病医生对强迫症的治疗。
J Clin Psychiatry. 2006 Jun;67(6):946-51. doi: 10.4088/jcp.v67n0611.
3
An open clinical trial of cognitive-behaviour therapy in children and adolescents with obsessive-compulsive disorder administered in regular outpatient clinics.在普通门诊对患有强迫症的儿童和青少年进行认知行为疗法的开放性临床试验。
Behav Res Ther. 2007 Mar;45(3):577-89. doi: 10.1016/j.brat.2006.04.011. Epub 2006 Jul 11.
4
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.一项系统评价:抗精神病药物增效治疗难治性强迫症
Mol Psychiatry. 2006 Jul;11(7):622-32. doi: 10.1038/sj.mp.4001823. Epub 2006 Apr 4.
5
Response versus remission in obsessive-compulsive disorder.强迫症中的反应与缓解
J Clin Psychiatry. 2006 Feb;67(2):269-76. doi: 10.4088/jcp.v67n0214.
6
Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment.行为疗法可增强强迫症患者对药物治疗的反应。
J Clin Psychiatry. 2005 Sep;66(9):1169-75. doi: 10.4088/jcp.v66n0913.
7
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.全国共病调查复制研究中12个月内DSM-IV疾病的患病率、严重程度及共病情况。
Arch Gen Psychiatry. 2005 Jun;62(6):617-27. doi: 10.1001/archpsyc.62.6.617.
8
Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?关注奥氮平、喹硫平和利培酮长期治疗的代谢后果:有差异吗?
Int J Neuropsychopharmacol. 2005 Jun;8(2):153-6. doi: 10.1017/S1461145705005183. Epub 2005 Mar 21.
9
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.暴露与仪式预防、氯米帕明及其联合治疗强迫症的随机安慰剂对照试验。
Am J Psychiatry. 2005 Jan;162(1):151-61. doi: 10.1176/appi.ajp.162.1.151.
10
A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.一项针对对5-羟色胺再摄取抑制剂难治的强迫症患者加用喹硫平的双盲、随机、安慰剂对照试验。
J Clin Psychiatry. 2004 Aug;65(8):1040-8. doi: 10.4088/jcp.v65n0803.

一项关于认知行为疗法辅助强迫症药物治疗的随机对照试验。

A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

作者信息

Simpson Helen Blair, Foa Edna B, Liebowitz Michael R, Ledley Deborah Roth, Huppert Jonathan D, Cahill Shawn, Vermes Donna, Schmidt Andrew B, Hembree Elizabeth, Franklin Martin, Campeas Raphael, Hahn Chang-Gyu, Petkova Eva

机构信息

Anxiety Disorders Clinic, New York State Psychiatric Institute, Unit 69, 1051 Riverside Dr., New York, NY 10032, USA.

出版信息

Am J Psychiatry. 2008 May;165(5):621-30. doi: 10.1176/appi.ajp.2007.07091440. Epub 2008 Mar 3.

DOI:10.1176/appi.ajp.2007.07091440
PMID:18316422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3945728/
Abstract

OBJECTIVE

Although serotonin reuptake inhibitors (SRIs) are approved for the treatment of obsessive-compulsive disorder (OCD), most OCD patients who have received an adequate SRI trial continue to have clinically significant OCD symptoms. The purpose of this study was to examine the effects of augmenting SRIs with exposure and ritual prevention, an established cognitive-behavioral therapy (CBT) for OCD.

METHOD

A randomized, controlled trial was conducted at two academic outpatient clinics to compare the effects of augmenting SRIs with exposure and ritual prevention versus stress management training, another form of CBT. Participants were adult outpatients (N=108) with primary OCD and a Yale-Brown Obsessive Compulsive Scale total score > or = 16 despite a therapeutic SRI dose for at least 12 weeks prior to entry. Participants received 17 sessions of CBT (either exposure and ritual prevention or stress management training) twice a week while continuing SRI pharmacotherapy.

RESULTS

Exposure and ritual prevention was superior to stress management training in reducing OCD symptoms. At week 8, significantly more patients receiving exposure and ritual prevention than patients receiving stress management training had a decrease in symptom severity of at least 25% (based on Yale-Brown Obsessive Compulsive Scale scores) and achieved minimal symptoms (defined as a Yale-Brown Obsessive Compulsive Scale score < or = 12).

CONCLUSIONS

Augmentation of SRI pharmacotherapy with exposure and ritual prevention is an effective strategy for reducing OCD symptoms. However, 17 sessions were not sufficient to help most of these patients achieve minimal symptoms.

摘要

目的

尽管5-羟色胺再摄取抑制剂(SRIs)已被批准用于治疗强迫症(OCD),但大多数接受过足够疗程SRIs治疗的强迫症患者仍有临床上显著的强迫症症状。本研究的目的是检验采用暴露与仪式行为阻止法(一种已确立的强迫症认知行为疗法(CBT))增强SRIs治疗的效果。

方法

在两家学术门诊诊所进行了一项随机对照试验,以比较采用暴露与仪式行为阻止法增强SRIs治疗与压力管理训练(另一种CBT形式)的效果。参与者为成年门诊患者(N = 108),患有原发性强迫症,且在入组前尽管接受了至少12周的治疗性SRIs剂量,但耶鲁-布朗强迫症量表总分≥16分。参与者在继续接受SRIs药物治疗的同时,每周接受两次共17节的CBT(暴露与仪式行为阻止法或压力管理训练)。

结果

在减轻强迫症症状方面,暴露与仪式行为阻止法优于压力管理训练。在第8周时,接受暴露与仪式行为阻止法治疗的患者中,症状严重程度至少降低25%(基于耶鲁-布朗强迫症量表评分)并达到最小症状(定义为耶鲁-布朗强迫症量表评分≤12分)的患者显著多于接受压力管理训练的患者。

结论

采用暴露与仪式行为阻止法增强SRIs药物治疗是减轻强迫症症状的有效策略。然而,17节治疗不足以帮助大多数此类患者达到最小症状。